carcinogenicity is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-23. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
=== Generalized ensembles === The replica exchange method is a generalized ensemble. It was originally created to deal with the slow dynamics of disordered spin systems. It is also called parallel tempering. The replica exchange MD (REMD) formulation tries to overcome the multiple-minima problem by exchanging the temperature of non-interacting replicas of the system running at several temperatures.
Evans' successor Lawrence Quincy Mumford took over in 1953. During his tenure, lasting until 1974, Mumford directed the initiation of construction of the James Madison Memorial Building, the third Library of Congress building on Capitol Hill. Mumford led the library during the government's increased educational spending. The library was able to establish new acquisition centers abroad, including in Cairo and New Delhi. In 1967, the library began experimenting with book preservation techniques through a Preservation Office. This has developed as the most extensive library research and conservation effort in the United States. During Mumford's administration, the last significant public debate occurred about the Library of Congress's role as both a legislative and national library. Asked by Joint Library Committee chairman Senator Claiborne Pell (D-RI) to assess operations and make recommendations, Douglas Bryant of Harvard University Library proposed several institutional reforms. These included expanding national activities and services and various organizational changes, all of which would emphasize the library's federal role rather than its legislative role. Bryant suggested changing the name of the Library of Congress, a recommendation rebuked by Mumford as "unspeakable violence to tradition." The debate continued within the library community for some time.
4.A.1 The PTS Glucose-Glucoside (Glc) Family 4.A.2 The PTS Fructose-Mannitol (Fru) Family 4.A.3 The PTS Lactose-N,N'-Diacetylchitobiose-β-glucoside (Lac) Family 4.A.4 The PTS Glucitol (Gut) Family 4.A.5 The PTS Galactitol (Gat) Family 4.A.6 The PTS Mannose-Fructose-Sorbose (Man) Family 4.A.7 The PTS L-Ascorbate (L-Asc) Family
Sources: en.wikipedia.org
Individuals with this disorder typically experience progressive muscle weakness of the leg and pelvis muscles, which is associated with a loss of muscle mass (wasting). Muscle weakness also occurs in the arms, neck, and other areas, but is not as noticeably severe as in the lower half of the body. Calf muscles initially enlarge during the ages of 5–15 (an attempt by the body to compensate for the loss of muscle strength), but the enlarged muscle tissue is eventually replaced by fat and connective tissue (pseudohypertrophy) as the legs become less used (with use of a wheelchair).
April 21, 1944: Women are granted the right to vote and to stand for election, by ordinance of the Provisional Government of the French Republic then located in Algiers. April 12, 1945: Ordinance on divorce and legal separation. April 29, 1945: First vote with women participating as voters, during municipal elections. September 1, 1945: Ordinance on paternal correction, notably abolishing the "right to paternal correction." October 4, 1945: Ordinance establishing Social Security; its provisions include the creation of mandatory maternity leave (14 weeks) with compensation amounting to half of the salary. October 9, 1945: Creation of the National School of Administration (ENA), which accepts women, provided they do not seek positions strictly reserved for men. October 19, 1945: Ordinance establishing the French Nationality Code. November 2, 1945: Ordinance on maternal and child protection. April 11, 1946: Law allowing women to access the judiciary. April 13, 1946: Ban on brothels and strengthening the fight against pimping, by the so-called "Marthe Richard law." April 24, 1946: Law establishing a sanitary and social registry of prostitution. May 18, 1946: Law granting an additional leave to heads of household, whether salaried, civil servants, or public service agents, for each birth in their household. July 30, 1946: Order repealing provisions allowing wage reductions for "female wages." August 22, 1946: Law establishing the family benefits system.
According to Mathieu Boisvert, nidana 3-10 correlate with the five skandhas. Boisvert notes that while sañña, "perception", is not found in the twelvefold chain, it does play a role in the processes described by the chain, particularly between feeling and the arising of samskaras. Likewise, Waldron notes that the anusaya, "underlying tendencies, are the link between the cognitive processes of phassa ("contact") and vedana (feeling), and the afflictive responses of tanha ("craving") and upadana ("grasping").
The taxonomic workforce remains insufficient for documenting lichen diversity. Lendemer (2021) found that only 14% of lichen-related research papers published in 2018–2020 included taxonomic work, while Lücking (2020) estimated that the current community of lichen taxonomists is only a fraction of what would be needed for a complete inventory. Expertise is particularly lacking in biodiversity-rich tropical regions where most undescribed species likely occur. However, infrastructure improvements are helping address these gaps. Since 2012–2013, mandatory registration of new fungal names in repositories like MycoBank has been widely adopted, with over 97% of new lichen species from 2018 to 2020 properly registered. Additionally, citizen scientists using platforms such as iNaturalist increasingly contribute to species discovery when collaborating with professional taxonomists. Nomenclatural challenges arise as lichen systematics increasingly encounters cryptic species. Environmental DNA studies reveal numerous uncharacterized fungal lineages, including potential lichenicolous fungi, but ICN rules require physical type specimens for species description. This creates difficulties for documenting diversity found only in environmental samples. The community generally discourages naming taxa known only from sequences to avoid proliferating dubious names. A related concern is taxonomic inflation—the risk that genomic data could lead to naming every population variant.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.